SYDNEY – November 02, 2026 -- Kazia Therapeutics (NASDAQ: KZIA) will present two preclinical abstracts on its lead asset paxalisib at the San Antonio Breast Cancer Symposium (SABCS), held Dec. 8-11, 2026, in San Antonio, Texas.

RALEIGH – November 02, 2026 -- RedHill Biopharma (NASDAQ: RDHL) said two independent in vitro studies confirmed that its Crohn's disease candidate RHB-204 kills Mycobacterium avium subspecies paratuberculosis (MAP) at a level comparable to RHB-104, which posted a 64% efficacy gain in a Phase 3 trial.

BAD HOMBURG – – November 02, 2026 -- Fresenius has secured exclusive rights to up to 37 biosimilar candidates under a development agreement with WuXi Biologics. The company calls it the largest development agreement announced in the biosimilars industry to date. The deal could lift Fresenius' portfolio from 29 marketed and pipeline molecules today to as many as 66 over the next decade, addressing more than €370 billion in originator list-price-based sales.

Shanghai – October 31, 2026 -- Shanghai Zhimeng Biopharma has completed enrollment of 255 patients in the pivotal Phase 2/3 trial of CB03-154 for amyotrophic lateral sclerosis (ALS), moving the potassium channel opener toward topline data and a possible new drug application in China.

Warren – October 31, 2026 -- PTC Therapeutics (NASDAQ: PTCT) granted stock options on 9,620 shares and 11,535 restricted stock units to 13 new employees, with the options struck at $63.02 per share.

Compensation Committee approved the grants on Oct. 28 under Nasdaq's inducement exception

The awards were made under the Nasdaq inducement grant exception, Listing Rule 5635(c)(4). PTC describes them as material to each employee's decision to accept employment. The options are non-statutory.

BOSTON – October 30, 2026 -- Medicilon presented Revolution Medicines, Inc. with its "Excellence in Client Partnership Award" after more than three years of joint work on pan-KRAS drug discovery, following the U.S. FDA's August 2026 approval of the NDA for Daraxonrasib in metastatic pancreatic cancer.

TAIPEI – October 30, 2026 -- HanchorBio (TWSE: 7827) has received Taiwan Food and Drug Administration approval for the Investigational New Drug application for HCB303, its trispecific TIGIT-Fc ligand-trap fusion protein, following U.S. FDA clearance. The approval was granted to its wholly owned subsidiary, FBD Biologics Limited, and gives the asset regulatory authorization for clinical investigation in two jurisdictions.

Bridgewater, N.J. – October 30, 2026 -- RVL Pharmaceuticals reported double-digit year-over-year revenue growth in the third quarter, driven by rising consumer demand for its prescription eye drop Upneeq, a national celebrity campaign and a widened product line.

Shelton – October 30, 2026 -- Intensity Therapeutics (Nasdaq: INTS) will report third-quarter 2026 financial results before the market opens on November 5, 2026, with management hosting a live webcast and conference call at 8:00 a.m. Eastern time to review the numbers and give a corporate update.

The quarter covers the period ended September 30, 2026. An archived webcast will be available for replay shortly after the call ends.

Mumbai – October 30, 2026 -- The U.S. Food and Drug Administration has approved Sun Pharma's supplemental Biologics License Application for ILUMYA (tildrakizumab-asmn) in adults with active psoriatic arthritis (PsA), the first expansion of the IL-23 inhibitor beyond plaque psoriasis since its 2018 U.S. approval.